The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated
